As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
18 Analysts have issued a Iovance Biotherapeutics Inc forecast:
18 Analysts have issued a Iovance Biotherapeutics Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 242 242 |
637%
637%
|
|
Gross Profit | 50 50 |
442%
442%
|
|
EBITDA | -360 -360 |
16%
16%
|
EBIT (Operating Income) EBIT | -411 -411 |
11%
11%
|
Net Profit | -390 -390 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Head office | United States |
CEO | Frederick Vogt |
Employees | 838 |
Founded | 2007 |
Website | www.iovance.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.